CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system (CNS). The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is in development for the treatment of a number of serious brain and CNS oncology indications, including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. In addition, the Company is advancing the development of its WP1244/WP1874 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents. The Company is also evaluating the use of WP1244/WP1874 in the treatment of other primary brain and central nervous system cancers, as well as cancers metastatic to the brain including pancreatic, ovarian, and lymphomas.

Employees

Sector

Biotechnology & Medical Research

Calendar

May. 17 - Q1 2026 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
25-12-11	7.654 $	+1.65%	12,863
25-12-10	7.530 $	+7.67%	52,264
25-12-09	6.993 $	-3.00%	5,635
25-12-08	7.210 $	+9.24%	22,385
25-12-05	6.600 $	+1.38%	8,606

Delayed Quote Nasdaq, December 11, 2025 at 04:30 pm EST

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

7.654USD

Average target price

20.00USD

Spread / Average Target

+161.30%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 04:30:00 2025-12-11 pm EST			5-day change	1st Jan Change
7.654 ^USD	+1.65%		+17.57%	-89.40%

Nov. 17	CNS Pharmaceuticals, Inc. - Shareholder/Analyst Call
Nov. 14	CNS Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI

Capitalization	4.75M 4.04M 3.77M 3.54M 6.54M 428M 7.12M 43.94M 17.07M 202M 17.82M 17.44M 737M	P/E ratio 2025 *	-0.28x	P/E ratio 2026 *	-1.21x
Enterprise value	4.75M 4.04M 3.77M 3.54M 6.54M 428M 7.12M 43.94M 17.07M 202M 17.82M 17.44M 737M	EV / Sales 2025 *	-	EV / Sales 2026 *	-
Free-Float	75.89%	Yield 2025 *	-	Yield 2026 *	-

Nov. 17	CNS Pharmaceuticals, Inc. - Shareholder/Analyst Call
Nov. 14	CNS Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
Aug. 21	Top Premarket Decliners	MT
Aug. 14	CNS Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
Jun. 27	Certain Options of CNS Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 28-JUN-2025.	CI
Jun. 27	Certain Restricted Stock Units of CNS Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 28-JUN-2025.	CI
Jun. 27	Certain Warrants of CNS Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 28-JUN-2025.	CI
Jun. 27	Certain Pre-Funded Warrants of CNS Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 28-JUN-2025.	CI
May. 15	CNS Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
May. 13	Sector Update: Health Care Stocks Fall Tuesday	MT
May. 13	Sector Update: Health Care Stocks Decline Tuesday Afternoon	MT
May. 13	Wall Street Set to Open Mixed Tuesday as Inflation Reading Lower Than Expected	MT
May. 13	Sector Update: Health Care Stocks Mixed Premarket Tuesday	MT

24-06-26	Top Midday Decliners	MT
22-08-17	Maxim Downgrades CNS Pharmaceuticals to Hold From Buy	MT
21-02-02	CNS PHARMACEUTICALS : Brookline Capital Initiates Coverage on CNS Pharmaceuticals at Buy Rating, Sets Price Target at $10	MT
20-12-28	CNS PHARMACEUTICALS : Ladenburg Thalmann Downgrades CNS Pharmaceuticals to Neutral From Buy	MT

CNS Pharmaceuticals, Inc. Stock

Equities

CNSP

US18978H5081

Biotechnology & Medical Research

Valuation: CNS Pharmaceuticals, Inc.

Chart: CNS Pharmaceuticals, Inc.

Latest news: CNS Pharmaceuticals, Inc.

Last Transcript: CNS Pharmaceuticals, Inc.

Analysts' recommendations: CNS Pharmaceuticals, Inc.

Press Releases: CNS Pharmaceuticals, Inc.

News in other languages: CNS Pharmaceuticals, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: CNS Pharmaceuticals, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

Nov. 17	CNS Pharmaceuticals : Reports Third Quarter 2025 Financial Results and Provides Corporate Update	PU
Nov. 10	CNS Pharmaceuticals : Announces Acceptance of Three Abstracts for Poster Presentation at the Society of NueroOncology (SNO) 30th Annual Meeting	PU
Aug. 28	CNS Pharmaceuticals, Inc. - IBN Announces Latest Episode of The BioMedWire Podcast Featuring John Climaco, CEO of CNS Pharmaceuticals Inc.	AQ
Aug. 27	IBN Announces Latest Episode of The BioMedWire Podcast Featuring John Climaco, CEO of CNS Pharmaceuticals Inc.	AQ
Aug. 18	CNS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Update	AQ

21-10-01	WPD Pharmaceuticals Inc.: WPD Pharmaceuticals gibt die Ergebnisse der Jahreshauptversammlung und außerordentlichen Versammlung bekannt
21-09-02	WPD Pharmaceuticals Inc.: WPD Pharmaceuticals kündigt für den 29. September Hauptversammlung an; plant anderen Weg zur Kapitalbeschaffung durch Delisting; WPD Polen arrangiert zusätzliche Kredite; Kommunikationsberater in Polen
21-07-12	IRW-PRESS : WPD Pharmaceuticals Inc.: Der Lizenzgeber von WPD Pharmaceuticals erhält FDA-Fast-Track-Status für Berubicin zur Behandlung von rezidivierendem Glioblastoma Multiforme; WPD Polen arrangiert Darlehen
21-06-28	IRW-PRESS : WPD Pharmaceuticals Inc.: WPD Pharmaceuticals plant Beginn von Phase Ib/II-Studie mit Berubicin zur Behandlung von Glioblastom in der zweiten Jahreshälfte 2021
21-05-11	IRW-PRESS : WPD Pharmaceuticals Inc.: WPD Pharmaceuticals erhält einen Zuschuss von 6,7 Millionen Dollar für die Entwicklung von Annamycin-Arzneimittelkandidaten

1 day	+1.65%
1 week	+17.57%
Current month	+10.29%
1 month	+13.73%
3 months	+1.78%
6 months	-31.42%
Current year	-89.40%

1 week	6.69	8.1
1 month	6.04	8.1
Current year	4.93	114
1 year	4.93	114
3 years	4.93	132,000.13
5 years	4.93	1,000,000
10 years	4.93	1,000,000

Manager	Title	Age	Since
John Climaco CEO	Chief Executive Officer	56	2017-08-31
Christopher Downs DFI	Director of Finance/CFO	46	2019-11-12
Sandra Silberman CTO	Chief Tech/Sci/R&D Officer	70	2017-11-30

Director	Title	Age	Since
John Climaco CHM	Chairman	56	2017-08-31
Jerzy Gumulka BRD	Director/Board Member	75	2017-11-07
Jeffry Keyes BRD	Director/Board Member	52	2018-06-24

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
CNS PHARMACEUTICALS, INC.	+1.65%	+17.57%	-88.10%	-99.99%	4.67M
ARGENX SE	-1.74%	-4.47%	+30.44%	+104.87%	54.9B
INSMED INCORPORATED	+2.84%	-4.78%	+163.13%	+957.64%	40.49B
WUXI APPTEC CO., LTD.	+0.70%	+4.25%	+61.90%	+16.75%	39.05B
BIONTECH SE	+0.28%	0.00%	-19.56%	-43.63%	23.02B
GENMAB A/S	+2.74%	-0.78%	+33.20%	-36.30%	19.13B
WUXI BIOLOGICS (CAYMAN) INC.	-0.36%	+2.27%	+83.70%	-35.66%	17.81B
SUMMIT THERAPEUTICS INC.	+0.28%	-4.36%	-4.16%	+358.93%	13.83B
AKESO, INC.	+2.90%	-2.66%	+83.31%	+200.87%	13.83B
MADRIGAL PHARMACEUTICALS, INC.	+3.41%	-2.54%	+86.37%	+753.88%	12.55B
Average	+1.27%	+1.12%	+43.02%	+217.74%	23.46B
Weighted average by Cap.	+0.79%	-1.21%	+62.00%	+255.97%

	2025 *	2026 *
Net sales	-	-
Net income	-12.75M -10.85M -10.13M -9.5M -17.57M -1.15B -19.12M -118M -45.84M -543M -47.84M -46.82M -1.98B	-13.06M -11.11M -10.38M -9.73M -18M -1.18B -19.6M -121M -46.97M -557M -49.02M -47.98M -2.03B
Net Debt	-	-